

## COMMENTARY

In their manuscript, Seeman and colleagues propose that atypical antipsychotic drugs may be distinguished from typical antipsychotic drugs by either their low affinity for  $D_2$  dopamine receptors or their selectivity for  $D_4$  dopamine receptors. The idea that atypical antipsychotic drugs have a relatively low affinity for  $D_2$  dopamine receptors is a now widely accepted view since others (Meltzer et al. 1989; Roth et al. 1995) have previously reported that atypical antipsychotic drugs as a group tend to have significantly lower affinities for  $D_2$  dopamine receptors than typical antipsychotic drugs.

Some of the other conclusions that Seeman and colleagues arrive at are not uniformly held, however. This commentary focuses on the second conclusion of Seeman and colleagues; namely, that some atypical antipsychotic drugs are selective for  $D_4$  dopamine receptors. In arriving at this conclusion, Seeman and colleagues cite an earlier work (Roth et al. 1995) and state that "perlapine, olanzapine, and clozapine are (found to be) selective for the dopamine  $D_4$  receptor, compared to the dopamine  $D_2$  receptor." Of the three compounds, only perlapine was actually selective with a  $D_2:D_4$  ratio of 63, but olanzapine ( $D_2:D_4 = 4.6$ ) and clozapine ( $D_2:D_4 = 5.3$ ) can only be said to *prefer*  $D_4$  over  $D_2$  receptors. Using the numbers supplied in Table 1 by Seeman and colleagues, generally lower selectivity ratios are found with perlapine (2) olanzapine (1.85), and clozapine (28). One could argue that clozapine is moderately selective for  $D_4$  receptors, but this is clearly not the case for the other ligands studied.

It also should be noted that clozapine and related atypical antipsychotic drugs have high affinities for a number of other neurotransmitter receptors. For instance, using [ $^3H$ ]-clozapine, Glatt, et al. (1995) demonstrated that clozapine's primary receptor sites in the brain resembled muscarinic and the 5-HT $_6$ -like serotonin receptors. In addition, we and others have demonstrated (Meltzer et al. 1989; Roth et al. 1992, 1994) that clozapine and other atypicals had high affinities for at least four serotonin receptors, including the 5-HT $_{2A}$ , 5-HT $_{2C}$ , 5-HT $_6$ , and 5-HT $_7$ . In fact, most of the tested atypical antipsychotic drugs had *higher* affinities for one or more of these four serotonin receptors than for the  $D_2$  dopamine receptor. In many instances, the affinities for one or more serotonin receptors were also *higher than their*  $D_4$  dopamine receptor affinities (Roth et al. 1994, 1995). In this regard, it should be noted that many of the new and therapeutically effective atypical

antipsychotic drugs (e.g., sertindole, olanzapine, seroquel, risperidone, and ziprasidone) were developed with a specific preference for 5-HT $_{2A}$  over  $D_2$  dopamine receptors.

Why then all the fuss about the  $D_4$  dopamine receptor? Seeman and colleagues give several reasons why the  $D_4$  dopamine receptor may be a more attractive target for atypical antipsychotic drug development than other neurotransmitter receptors. This commentary focuses on three. First, Seeman and colleagues cite prior studies in which they and others found elevated amounts of " $D_4$ -like receptors" in schizophrenic striata (Seeman et al. 1993; Murray et al. 1995; Sumiyoshi et al. 1995). More recent studies (Lahti et al. 1996) using a  $D_4$ -selective radioligand found that  $D_4$  receptors are virtually absent in both control and schizophrenic striata. These findings would appear to negate this particular justification for using the  $D_4$  receptor as a target of drug development.

Second, Seeman and colleagues speculate that  $D_4$  dopamine receptors might "mitigate against the extrapyramidal side effects of dopamine  $D_2$  antagonists by activating locomotion." Because there are few, if any,  $D_4$  receptors in the striatum, it is difficult to imagine how this could occur. The authors state, in this regard, that "nafadotride, for example, a  $D_3$  receptor antagonist, activates locomotion in rats (Sautel et al. 1995)." There is no reason to believe, however, that because a  $D_3$  antagonist activates locomotion a  $D_4$  antagonist will do the same.

Third, Seeman and colleagues find that the 5-HT $_{2A}:D_2$  ratio proposed by others (Meltzer et al. 1989; Leysen et al. 1994) is not uniformly able to distinguish typical and atypical antipsychotic drugs. Part of their main argument derives from the use of "radioligand-independent dissociation constants" that, superficially at least, appear to represent a more precise manner of measuring drug affinities for receptors. Without discussing the rationale behind the analysis, several inconsistencies were noted for the 5-HT $_{2A}$  data. In particular, the plots for several of the compounds (fluphenazine, haloperidol, seroquel, and thioridazine) had positive slope factors. How could the dissociation constant possibly increase while the partition coefficient decreases? Because only two data points were used by Seeman and colleagues to calculate the "radioligand-independent dissociation constants," these values are not particularly reliable.

In conclusion, Seeman and colleagues have persuasively argued that atypical antipsychotic drugs have a rel-

atively low affinity for D<sub>2</sub> dopamine receptors. About this conclusion there is little disagreement. Clinical trials with D<sub>4</sub>-selective compounds are under way, and based on early animal testing one can predict that these compounds might be of little utility as discrete therapeutic agents for treating active psychosis. With respect to the D<sub>4</sub> dopamine receptors and the treatment of schizophrenia, there has been much sound and fury, but little bona fide significance.

### ACKNOWLEDGMENTS

This work was supported in part by Research Scientist Development Award KO2 MH 01366 from NIMH, RO1 GM52213 from NIGMS, and a grant from the Scottish Rite Schizophrenia Research Foundation to BLR.

Bryan L. Roth, M.D., and David R. Sibley, Ph.D.  
Department of Psychiatry, Neurosciences, and Biochemistry  
Case Western Reserve University Medical School  
Cleveland, Ohio

### REFERENCES

- Glatt CE, Snowman AM, Sibley DR, Snyder SH (1995): Clozapine-selective labelling of sites resembling 5-HT<sub>6</sub> serotonin receptors may reflect psychoactive profile. *Mol Medicine* 1:398–406
- Lahti RA, Primus RJ, Gallager DW, Roberts R, Tamminga CA (1996): Distribution of dopamine D<sub>4</sub> receptor in human postmortem brain sections: Autoradiographic studies with [<sup>3</sup>H]-NGD-94-1. *Schizophrenia Res* 18:173
- Leysen JE, Megens AAHH, Janssen PMF, Schotte A (1994): Finely balanced 5-HT<sub>2</sub>/D<sub>2</sub> antagonism: A crucial factor for the treatment of schizophrenia. *Neuropsychopharmacology* 10(suppl 3):467S
- Meltzer HY, Matsubara S, Lee J-C (1989): Classification of typical and atypical antipsychotic drugs on the basis of dopamine D<sub>1</sub>, D<sub>2</sub> and serotonin<sub>2</sub> pK<sub>i</sub> values. *J Pharmacol Exp Ther* 251:238–246
- Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE (1995): Distribution of putative D<sub>4</sub> dopamine receptors in postmortem striatum from patients with schizophrenia. *J Neurosci* 15:2186–2191
- Roth BL, Ciaranello RD, Meltzer HY (1992): Binding of typical and atypical antipsychotic agents with transiently expressed 5-HT<sub>1c</sub> receptors. *J Pharmacol Exp Ther* 260:1360–1365
- Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994): Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine<sub>6</sub> and 5-hydroxytryptamine<sub>7</sub> receptors. *J Pharmacol Exp Ther* 268:1403–1410
- Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995): D<sub>4</sub> dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. *Psychopharmacology* 120:360–365.
- Sautel F, Griffon N, Sokoloff P, Schwartz, J-C, Launay C, Simon P, Costentin J, Schonfelder A, Garrido F, Mann A, Wermuth CG (1995): Nafadotride, a potent preferential dopamine D<sub>3</sub> receptor antagonist, activates locomotion in rats. *J Pharmacol Exp Ther* 275:1239–1246
- Seeman P, Guan H-C, Van Tol HHM (1993): Dopamine D<sub>4</sub> receptors are elevated in schizophrenia. *Nature* 365:441–445
- Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY (1995): Dopamine D<sub>4</sub> receptors and effects of guanine nucleotides on [<sup>3</sup>H]-raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. *Brain Res* 681:109–116